Mast Therapeutics Inc (NASDAQ:MSTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.

According to Zacks, “Mast Therapeutics Inc. is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments. The company’s lead product candidate is MST-188 for treating serious or life-threatening diseases. Mast Therapeutics, Inc., formerly known as ADVENTRX Pharmaceuticals, Inc., is based in San Diego, California. “

MSTX has been the subject of a number of other research reports. Maxim Group set a $5.00 target price on Mast Therapeutics and gave the stock a “buy” rating in a research report on Thursday, September 8th. Laidlaw downgraded Mast Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 21st. Cowen and Company downgraded Mast Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Friday, September 23rd. Roth Capital reiterated a “buy” rating and issued a $2.00 price objective on shares of Mast Therapeutics in a research report on Friday, July 15th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $3.00 price objective on shares of Mast Therapeutics in a research report on Thursday, July 28th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $2.56.

Analyst Recommendations for Mast Therapeutics (NASDAQ:MSTX)

Shares of Mast Therapeutics (NASDAQ:MSTX) opened at 0.0862 on Wednesday. Mast Therapeutics has a 52-week low of $0.08 and a 52-week high of $0.71. The firm’s 50-day moving average is $0.33 and its 200-day moving average is $0.36. The firm’s market cap is $18.26 million.

Mast Therapeutics (NASDAQ:MSTX) last released its earnings results on Tuesday, August 9th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. Analysts anticipate that Mast Therapeutics will post ($0.19) earnings per share for the current year.

An institutional investor recently raised its position in Mast Therapeutics stock. Vanguard Group Inc. raised its stake in Mast Therapeutics Inc (NASDAQ:MSTX) by 18.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,996,047 shares of the company’s stock after buying an additional 923,507 shares during the period. Vanguard Group Inc. owned 3.11% of Mast Therapeutics worth $2,818,000 at the end of the most recent reporting period.

Mast Therapeutics Company Profile

Mast Therapeutics, Inc is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options.

5 Day Chart for NASDAQ:MSTX

Get a free copy of the Zacks research report on Mast Therapeutics (MSTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mast Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc and related companies with's FREE daily email newsletter.